Huahai Pharmaceutical Receives Clinical Trial Approval for Voriconazole for Injection

On March 25, Huahai Pharmaceutical issued an announcement stating that it had recently received the "Notice of Approval for Drug Clinical Trials" for Voriconazole for Injection from the National Medical Products Administration.

Voriconazole for Injection is a broad-spectrum triazole antifungal agent; the original research company is Pfizer, in October 2004approved for domestic marketing authorization in [Month]. Currently, the approved enterprises in China include Livzon Pharmaceutical Factory of Livzon Group and Jincheng Haisi Pharmaceutical Co., Ltd.The Company, Zhuhai Yibang Pharmaceutical Co., Ltd., and Sichuan Meidakang Huakang Pharmaceutical Co., Ltd. have not yet obtained approval.Consistency Evaluation of Quality and Efficacy for Generic Drugs.According to statistics, the sales revenue of Voriconazole for Injection in domestic tiered hospitals in China during the first three quarters of 2020 was approximately RMB 1.63 billion.Yuan (data sourced from the Xianda Database).

To date, Huahai Pharmaceutical has incurred a total of approximately RMB 8.79 million in research and development expenses for the Voriconazole for Injection project.